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The mechanism by which pharmacologic adminis-
tration of the hormone FGF21 increases energy
expenditure to cause weight loss in obese animals
is unknown. Here we report that FGF21 acts centrally
to exert its effects on energy expenditure and body
weight in obesemice. Using tissue-specific knockout
mice, we show that bKlotho, the obligate coreceptor
for FGF21, is required in the nervous system for these
effects. FGF21 stimulates sympathetic nerve activity
to brown adipose tissue through a mechanism that
dependson theneuropeptidecorticotropin-releasing
factor. Our findings provide an unexpected mecha-
nistic explanation for the strong pharmacologic ef-
fects of FGF21 on energy expenditure and weight
loss in obese animals.
INTRODUCTION
FGF21 is a hormone expressed in liver, where it is induced
by states of nutrient stress, including starvation and ketogenic
or high-carbohydrate diets, and the fibrate drugs. FGF21 is
also expressed in white adipose tissue (WAT), where it is induced
by fasting/refeeding regimens and the thiazolidinedione drugs,
and in brown adipose tissue (BAT), where it is induced by cold
(reviewed in Potthoff et al., 2012). In rodent models of obesity,
FGF21 administration caused weight loss by increasing energy
expenditure and improved insulin sensitivity and lipid parame-
ters (Coskun et al., 2008; Kharitonenkov et al., 2005; Xu et al.,
2009a, 2009b). Similar metabolic effects were seen in diabetic
rhesus monkeys and patients with type 2 diabetes (Gaich
et al., 2013; Kharitonenkov et al., 2007; Ve´niant et al., 2012b).
FGF21 acts through a cell surface receptor comprised of an
FGF receptor (FGFR), with FGFR1c the preferred isoform, in
complex with bKlotho (reviewed in Potthoff et al., 2012). While
the FGFRs are broadly expressed, bKlotho is expressed in a
more limited set of tissues, including WAT, BAT, and liver (Fon
Tacer et al., 2010). FGF21 mediates its pharmacologic effects670 Cell Metabolism 20, 670–677, October 7, 2014 ª2014 Elsevier Inon body weight and insulin sensitivity in part through WAT and
BAT (Adams et al., 2012; Ding et al., 2012; Ve´niant et al.,
2012a; Wu et al., 2011), where it induces uncoupling protein-1
(Ucp1) and uncoupled respiration (Fisher et al., 2012; Hondares
et al., 2010) and the hormone adiponectin (Holland et al., 2013;
Lin et al., 2013). FGF21 also acts on the nervous system.
FGF21 is not expressed in the CNS (Fon Tacer et al., 2010) but
crosses the blood-brain barrier (Hsuchou et al., 2007) and is pre-
sent in human cerebrospinal fluid (Tan et al., 2011). Intracerebro-
ventricular (i.c.v.) injection of FGF21 increased metabolic rate
and insulin sensitivity in rats (Sarruf et al., 2010). Within the
nervous system, bKlotho is expressed in the suprachiasmatic
nucleus (SCN) in the hypothalamus. It is also expressed in the
area postrema, nucleus of the solitary tract, and nodose ganglia,
which are discrete anatomical nuclei that together comprise the
dorsal-vagal complex (DVC) (Bookout et al., 2013). Using lean
mice specifically lacking bKlotho in the hypothalamus and/or
the hindbrain, we showed that bKlotho in the hypothalamus
is required for FGF21 to increase circulating ketone body and
glucocorticoid concentrations, to suppress growth and female
reproduction, and to modulate circadian behavior (Bookout
et al., 2013; Owen et al., 2013). However, since these studies
were all done in lean mice, they did not address whether the
effects of FGF21 on energy expenditure require that it act on
the nervous system. In this paper, we examine the contribution
of the nervous system to the pharmacologic actions of FGF21
in the context of diet-induced obesity (DIO).
RESULTS AND DISCUSSION
FGF21 Acts Centrally to Induce Energy Expenditure
Fgf21-transgenic (Tg) mice are resistant to weight gain (Ding
et al., 2012; Kharitonenkov et al., 2005). To determine whether
this effect involves FGF21 acting in the brain, we crossed
KlbCamk2a mice, in which the bKlotho gene (Klb) is disrupted in
both the hypothalamus (including the SCN) and DVC, but not
in adipose tissue and liver (Bookout et al., 2013), with Fgf21-Tg
mice to generate four genotypes: Klbfl/fl, Klbfl/fl/Tg, KlbCamk2a,
and KlbCamk2a/Tg mice. As expected (Inagaki et al., 2008),
Klbfl/fl/Tg mice weighed less than Klbfl/fl mice on the standard
chow diet due to their smaller body size, and this effect wasc.
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Figure 1. Klb Expression in the Nervous System Is Required for the Effects of FGF21 on Whole-Body Energy Expenditure
(A) Body weight in chow-fed groups of Klbfl/fl, Klbfl/fl/Tg, KlbCamk2a, and KlbCamk2a/Tg mice.
(B) Percent change in bodyweight in groups of mice fed a high-fat diet (HFD). Bodyweights for the groups at the end of the studywere as follows (in grams):Klbfl/fl,
44 ± 2.5; Klbfl/fl/Tg, 33 ± 1.7; KlbCamk2a, 40 ± 1.3; KlbCamk2a/Tg, 47 ± 2.6.
(C) Body composition after 8 weeks on HFD.
(D) Food consumption (normalized to body weight) and physical activity during a 24 hr period while on a HFD.
(E) Left: energy expenditure starting 24 hr after switching mice to the HFD. Right: quantification of 24 hr energy expenditure data for the same mice on either
regular chow or HFD.
(A)–(C) were performed with mice housed at 22–23. (D) and (E) were performed using metabolic cages maintained at 21–22.
Data are shown as the mean ± SEM. n = 8–13/group (A–C); n = 6/group (D and E). *p < 0.05 compared to control.
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FGF21 Activates the Sympathetic Nervous Systemabsent in KlbCamk2a/Tg mice (Figure 1A). When fed a high-fat
diet (HFD), Klbfl/fl/Tg mice gained less weight than Klbfl/fl and
KlbCamk2a mice (Figure 1B). These effects of FGF21 overexpres-
sion were lost in the KlbCamk2a/Tg mice (Figure 1B). HFD-fed
Klbfl/fl/Tg mice had a reduced percentage of fat mass and
plasma leptin concentrations and increased percentage of lean
mass compared to the other three genotypes (Figure 1C; Table
S1, available online). In metabolic cage studies, the Klbfl/fl/Tg
mice had significantly increased food consumption and energy
expenditure with no change in physical activity (Figures 1D
and 1E). This significant effect of FGF21 on energy expenditure
was not observed in the same mice fed a regular chow dietCell(Figure 1E), suggesting that oxidative substrate was limiting.
Together, these data demonstrate that in the context of nutri-
tional surfeit, FGF21 acts on the nervous system to stimulate
energy expenditure.
We further evaluated carbohydrate and lipid parameters in the
HFD-fed Klbfl/fl, Klbfl/fl/Tg, KlbCamk2a, and KlbCamk2a/Tg mice.
Plasma glucose, insulin, and cholesterol were all significantly
lower in Klbfl/fl/Tg mice than in the other three genotypes, and
plasma triglycerides showed a similar trend (Table S1). Likewise,
hepatic cholesterol and triglyceride concentrations were sig-
nificantly lower in Klbfl/fl/Tg mice than in the other genotypes
(Table S1).Metabolism 20, 670–677, October 7, 2014 ª2014 Elsevier Inc. 671
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FGF21 Activates the Sympathetic Nervous SystemFGF21 Acts Centrally to Induce Thermogenic Genes
We next compared gene expression in BAT, subcutaneous (sc)
and epididymal (e) WAT and liver of Klbfl/fl, Klbfl/fl/Tg, KlbCamk2a,
and KlbCamk2a/Tg mice. As expected, Klb was unchanged in
BAT, scWAT, eWAT, and liver of KlbCamk2a compared to Klbfl/fl
mice, although FGF21 overexpression increased Klb mRNA in
eWAT in Klbfl/fl, but not KlbCamk2a, mice (Figures 2A–2D). There
were no differences among genotypes in Fgfr1c expression.
In BAT, Ucp1, deiodinase 2 (Dio2), and elongation of very long
chain fatty acids like 3 (Elovl3) were elevated in Klbfl/fl/Tg
compared to Klbfl/fl mice, consistent with increased thermogen-
esis (Figure 2A). Interestingly, bone morphogenic protein 8b
(Bmp8b), which is induced in BAT in response to cold or HFD
feeding and sensitizes BAT to the thermogenic actions of norepi-
nephrine (Whittle et al., 2012), was increased markedly in Klbfl/fl/
Tg mice compared to Klbfl/fl controls (Figure 2A). In scWAT,
Ucp1, peroxisome proliferator-activated receptor g (Pparg),
phosphoenolpyruvate carboxykinase (Pck1), adipocyte triacyl-
glycerol lipase (Atgl), hormone-sensitive lipase (Hsl), acetyl-
CoA carboxylase a (Acaca), stearoyl-coenzyme A desaturase 1
(Scd1), and adiponectin (Adipoq) were increased in Klbfl/fl/Tg
compared to Klbfl/fl controls (Figure 2B). The induction of Ucp1
is consistent with a recent report showing that FGF21 causes
browning of WAT (Fisher et al., 2012). In eWAT, Pparg, PPARg
coactivator-1a (Pgc1a), Pck1, Atgl, Hsl, Acaca, Scd1, and
Adipoq were increased in Klbfl/fl/Tg compared to Klbfl/fl mice
(Figure 2C). All of these FGF21-dependent changes in gene
expression were lost in KlbCamk2a/Tg mice (Figures 2A–2C),
demonstrating that bKlotho in the nervous system is important
for FGF21 to exert many of its pharmacologic effects on gene
expression in adipose tissue. Since FGF21 also acts directly
on adipocytes to induce Ucp1 and other genes (Fisher et al.,
2012; Hondares et al., 2010), their maximal induction likely
involves cooperative effects of FGF21 on both adipose tissue
and the nervous system. In liver, fatty acid synthase (Fasn),
Scd1, Acaca, Cd36, and Elovl6 were decreased in Klbfl/fl/Tg
compared to Klbfl/fl mice (Figure 2D). These inhibitory effects
of FGF21 were also absent in KlbCamk2a/Tg mice (Figure 2D).
A recent study showed that the effects of FGF21 on reducing
triglyceride and cholesterol concentrations were lost in liver-spe-
cific insulin receptor knockout mice (Emanuelli et al., 2014). Simi-
larly, the loss of FGF21 action in liver of KlbCamk2a/Tg mice may
be secondary to the loss of its insulin-lowering action (Table
S1). Expression of dual specificity phosphatase 4 (Dusp4), which
inhibits ERK1/2, was increased in Klbfl/fl/Tg mice compared
to Klbfl/fl mice in all three adipose tissue depots, but not liver
(Figures 2A–2D). Dusp4 was still increased in KlbCamk2a/Tg
compared to KlbCamk2a mice in BAT and eWAT (Figures 2A and
2C), reinforcing the notion that FGF21 can also act directly on
adipose tissue.
FGF21 Acts on the Hypothalamus
To assess the relative contribution of bKlotho in the DVC
versus the hypothalamus to the metabolic actions of FGF21,Figure 2. Klb Expression in the Nervous System Is Required for the Ef
(A–D) Gene expression was analyzed by qPCR in (A) brown adipose tissue (BAT),
(D) liver of Klbfl/fl, Klbfl/fl/Tg, KlbCamk2a, and KlbCamk2a/Tg mice after 3 months on t
expression for each gene. Data are shown as the mean ± SEM. n = 8–13/group.
Cellwe crossed Fgf21-Tg mice with KlbPhox2b mice, in which Klb
is disrupted in the DVC but not the hypothalamus (Bookout
et al., 2013). Metabolic parameters were evaluated in HFD-
fed Klbfl/fl, Klbfl/fl/Tg, KlbPhox2b, and KlbPhox2b/Tg mice. In
contrast to KlbCamk2a/Tg mice, KlbPhox2b/Tg mice were similar
to Klbfl/fl/Tg mice with respect to weight gain, energy expendi-
ture, and plasma insulin and glucose concentrations, although
the significance of the decrease in glucose was lost in the
KlbPhox2b/Tg mice (Figure S1A). Likewise, KlbPhox2b/Tg and
Klbfl/fl/Tg mice had comparable changes in the expression
of Ucp1 in BAT (Figure S1B). However, the significance of
Ucp1 induction in scWAT was lost in the KlbPhox2b/Tg mice
(Figure S1B). Overall, these data support the importance of
bKlotho in the hypothalamus and not the DVC for the central
actions of FGF21.
Since Fgf21-Tg mice are chronically exposed to high levels
of FGF21, we examined whether the metabolic effects of
shorter-term exposure to recombinant FGF21 in DIO mice
also require bKlotho in the nervous system. DIO Klbfl/fl and
KlbCamk2a mice were administered FGF21 or vehicle for 2 weeks
by osmotic minipump. Plasma FGF21 concentrations were 29 ±
11 ng/ml and 36 ± 13 ng/ml in the Klbfl/fl and KlbCamk2a mice,
respectively. As expected, FGF21 decreased body weight,
percent body fat, and plasma insulin, glucose, cholesterol,
and leptin concentrations in DIO Klbfl/fl mice (Figure 3A). All of
these effects of FGF21 were absent in the KlbCamk2a mice (Fig-
ure 3A). FGF21 administration also increased Ucp1 expression
in BAT and scWAT in Klbfl/fl, but not KlbCamk2a, mice (Figure 3B).
Overall, the pattern of gene expression in BAT, scWAT, eWAT,
and liver of Klbfl/fl and KlbCamk2a mice in response to recombi-
nant FGF21 was similar to that seen with the FGF21 transgene,
with nearly all of the effects of FGF21 lost in the KlbCamk2a
background (Figure S2). Thus, bKlotho in the nervous system
is required for the pharmacologic actions of FGF21 in DIO
mice.
FGF21 Induces Sympathetic Nerve Activity
Since BAT-mediated energy expenditure is regulated by the
sympathetic nervous system, we used multifiber sympathetic
nerve recording to directly measure the effect of FGF21 on
sympathetic nerve activity (SNA) subserving BAT in mice.
Injection of FGF21 i.c.v. increased BAT SNA in a time- and
dose-dependent manner (Figures 4A and 4B). SNA was
induced approximately 30 min after FGF21 administration and
continued to increase over the 4 hr experiment. This effect
was blocked by i.c.v. pretreatment with PD173074 (Figure
4B), which inhibits the tyrosine kinase activities of FGFR1,
FGFR2, and FGFR3 (Kunii et al., 2008; Mohammadi et al.,
1998). Intravenous (i.v.) injection of FGF21 also increased
BAT SNA, which was inhibited by i.c.v. pretreatment with
PD173074 (Figure 4C). The onset of SNA induction was
slower after i.v. injection compared to i.c.v. injection, as ex-
pected, since FGF21 must cross the blood-brain barrier. The
effect of FGF21 on SNA when administered peripherally wasfects of FGF21 on Gene Expression in HFD-Fed Mice
(B) subcutaneous (sc) white adipose tissue (WAT), (C) epididymal (e) WAT, and
he high-fat diet. qPCR cycle time values are shown for the group with highest
*p < 0.05 compared to control.
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Figure 3. Klb Expression in the Nervous System Is Required for
Metabolic Actions of Recombinant FGF21 Delivered by Minipump
(A andB)Groupsof diet-inducedobesemicewere administeredFGF21 (0.8mg/
kg/day) or vehicle by osmotic minipump for 2 weeks and evaluated for (A)
percent change in body weight (day 1 versus day 14), body composition, and
plasma insulin, glucose, cholesterol, and leptin concentrations (day 14) or (B)
uncoupling protein-1 (Ucp1) gene expression in brown adipose tissue (BAT) and
subcutaneous white adipose tissue (scWAT). For (A), body weights for the
groupsat theendof the studywere as follows (in grams):Klbfl/fl/vehicle, 34± 1.3;
Klbfl/fl/FGF21, 30 ± 1.0; KlbCamk2a/vehicle, 36 ± 1.6; KlbCamk2a/FGF21, 36 ± 1.3.
Data are shown as the mean ± SEM. n = 5–6/group. *p < 0.05 compared to
vehicle.
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FGF21 Activates the Sympathetic Nervous Systemmarkedly attenuated in KlbCamk2a mice (Figure 4D). The residual
effect of FGF21 on BAT SNA in the KlbCamk2a mice could be
due to either incomplete knockout of bKlotho in the nervous
system or FGF21 acting via other, unknown mechanisms.
Regardless, the data in Figure 1E show that bKlotho in the ner-
vous system is crucial for the effect of FGF21 on energy
expenditure.674 Cell Metabolism 20, 670–677, October 7, 2014 ª2014 Elsevier InFGF21 Actions Require Corticotropin-Releasing Factor
We previously showed that corticotropin-releasing factor
(Crf) mRNA in hypothalamus and circulating corticosterone con-
centrations are increased in Fgf21-Tg mice (Bookout et al.,
2013). Likewise, hypothalamic CrfmRNA was elevated 3 hr after
intraperitoneal injection of FGF21, and there was a correspond-
ing increase in plasma adrenocorticotropic hormone (ACTH)
(Figure 4E). While ACTH concentrations were increased under
these acute FGF21 treatment conditions, they were reduced af-
ter administration of FGF21 for 2 weeks and in Fgf21-Tg mice
(Bookout et al., 2013), suggesting that chronic FGF21 exposure
sensitizes the adrenal to ACTH. Indeed, there is evidence that
the autonomic nervous system can modulate the sensitivity of
the adrenal to ACTH (Kalsbeek et al., 2010). Since i.c.v. injection
of CRF stimulates sympathetic outflow to BAT and thermogene-
sis in rats (Arase et al., 1988; Cerri and Morrison, 2006; LeFeuvre
et al., 1987), we tested whether CRF contributes to the effects of
FGF21 on BAT. Notably, i.c.v. injection of the CRF receptor
antagonist, a-helical CRF(9-41) (Rivier et al., 1986), which inhibits
both the CRF1 and CRF2 receptor subtypes, completely
blocked the effect of FGF21 on SNA in BAT (Figure 4F). This
finding that FGF21 action involves downstream effects on CRF
likely explains the relatively slow onset of SNA in BAT in response
to FGF21. In the hypothalamus, bKlotho is most highly ex-
pressed in the SCN, whereas CRF is primarily localized in the
paraventricular nucleus (PVN). Since the SCN is known to act
on the PVN to regulate the circadian pattern of CRF and cortico-
sterone release (Kalsbeek et al., 2010), FGF21 may mediate its
effects on CRF indirectly via the SCN. However, the precise
neuroanatomical relationship between bKlotho andCRF remains
to be determined. Nevertheless, our findings suggest that FGF21
regulates both BAT SNA and corticosterone levels via its effects
on CRF.
In summary, wedemonstrate that FGF21 acts centrally to stim-
ulate sympathetic outflow, energyexpenditure, andweight loss in
DIOmice. We previously showed that the acute effects of FGF21
onwhole-body insulin sensitivity and glucose uptake in BATwere
lost in HFD-fedmice lacking bKlotho in adipose tissue (Ding et al.,
2012). How do we reconcile these findings? In vivo, the thermo-
genic effects of UCP1 require both norepinephrine and oxidative
substrate (Nedergaard et al., 2005). For example, while PPARg
agonists efficiently stimulateUcp1 expression and lipid accumu-
lation in both brown and white adipocytes, they do not increase
thermogenesis. However, they potentiate the thermogenic ac-
tions of b-adrenergic receptor agonists (Foellmi-Adams et al.,
1996; Sell et al., 2004; Thurlby et al., 1987). We suggest that
FGF21workssimilarly to this combinationofPPARgandb-adren-
ergic receptor agonists through a 2-fold mechanism (Figure 4G).
First, FGF21 acts on the nervous system to stimulate sympathetic
outflow to BAT, which induces Ucp1 and lipolysis (Cannon and
Nedergaard, 2004). FGF21alsopromotes thebrowningof scWAT
(Fisher et al., 2012), an effect that in vivo involves bKlotho in the
nervoussystem.Second, FGF21acts directly onBATand scWAT
to increase glucose uptake and substrate mobilization. Accord-
ingly, we find that energy expenditure is markedly upregulated
in lean Fgf21-Tg mice when they are switched to the HFD and
additional substrate is made available for oxidation (Figure 1E).
Thus, FGF21 regulates both the mobilization and uncoupled
oxidation of substrate in BAT and browned WAT.c.
Camk2a + FGF21
Time (min)60 120 180 2400
BA
T
SN
A
(%
)
-50
50
150
250
fl/fl + FGF21
Time (min)60 120 180 2400
BA
T
SN
A
(%
)
-100
0
100
200
300
Vehicle
FGF21
0.5 sec
1
vo
lt
Vehicle
FGF21
A
Time (min)60 120 180 2400
BA
T
SN
A
(%
)
-50
0
50
100
150
200
Vehicle
FGF21
PD173074
FGF21 ( g)
- -- + +
0 0.5 1 1 0
-50
0
50
100
150
200
BA
T
SN
A
(%
)
PD173074
FGF21 ( g/g)
- +-
0 1 1
-100
0
100
200
300
BA
T
SN
A
(%
)
0
50
100
150
200
250
Camk2afl/fl
BA
T
SN
A
(%
)
B
C
D
*
*
*
*
FGF21
SNA
Brain
Glucose uptake
Substrate mobilization
BATUCP1
Lipolysis
G
Heat
Cr
fm
R
N
A
(re
lat
ive
le
ve
ls
)
FGF21V
1
3
0
50
100
150
200
250
FGF21
+
hCRF(9-41)
FGF21
BA
T
SN
A
(%
)
*
F
AC
TH
(pg
/m
l)
FGF21V
200
400
600
800
0
E
0
2
* *
CRF
Figure 4. FGF21 Acts Centrally to Stimulate
Brown Adipose Tissue Sympathetic Nerve
Activity
(A) Representative sympathetic nerve activity
(SNA) recordings at baseline and 4 hr after intra-
cerebroventricular (i.c.v.) administration of FGF21
(1 mg) or vehicle.
(B) Left: percent change in BAT SNA following
i.c.v. injection of FGF21 (1 mg) or vehicle. Right:
percent change in BAT SNA at 3–4 hr following
i.c.v. injection of FGF21 at the indicated doses.
Mice were pretreated for 10 min with either vehicle
or an FGF receptor inhibitor (PD173074, 25 mg)
delivered i.c.v. as indicated.
(C) Left: percent change in BAT SNA following
intravenous (i.v.) injection of vehicle or FGF21
(1 mg/kg). Right: percent change in BAT SNA at
3–4 hr following i.v. injection of FGF21. Mice were
pretreated for 10 min with either PD173074 or
vehicle delivered i.c.v. as indicated.
(D) Left: percent change in BAT SNA following
i.v. injection of FGF21 (1 mg/kg) into Klbfl/fl or
KlbCamk2a mice. Right: quantification of SNA data
at the 3–4 hr time points.
(E) Crf mRNA levels in whole hypothalamus and
plasma adrenocorticotropic hormone (ACTH)
concentrations 3 hr after i.p. injection with either
vehicle or FGF21 (1 mg/kg).
(F) Percent change in BAT SNA 3–4 hr after i.c.v.
injection of FGF21 (1 mg). Mice were pretreated for
10 min with either vehicle (saline, 2 ml) or a-helical
CRF(9-41) (ahCRF(9-41); 6 mg) delivered i.c.v. as
indicated.
Data are shown as the mean ± SEM. n = 5–7/
group. *p < 0.05 compared to either vehicle (B, C,
and E) or Klbfl/fl (D) as determined by t test. For (B)–
(D) (right panels) and (F), the percent change in
BAT SNA was calculated based on the average of
the final four time points relative to baseline.
(G) Model for the effects of FGF21 on energy
expenditure. FGF21 acts on the hypothalamus to
induce corticotropin-releasing factor (CRF) and to
stimulate sympathetic nerve activity (SNA), which
in turn induces uncoupling protein-1 (UCP1) and
lipolysis in brown adipose tissue (BAT). FGF21 also
acts directly on BAT to stimulate glucose uptake
and to mobilize oxidative substrate. These dual
effects induce efficient energy expenditure. The
model is basedon this study andprevious literature
(Cannon and Nedergaard, 2004; Ding et al., 2012).
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Mouse Studies
Mouse strains have been described and are on mixed C57BL6J;129/Sv back-
grounds (Bookout et al., 2013; Owen et al., 2013). Age-matched 3- to 7-month-
old male littermates were used for all experiments and were fed either a
standard chow (Harlan Teklad, TD.2916) or a high-fat diet containing 60%
fat (Research Diets, D12492i). For the minipump experiments, mice were
maintained on the high-fat diet for 12 weeks prior to initiating the experiment.
Housing rooms were maintained between 22C and 23C. Metabolic cage
studies were performed at 21C–22C. Indirect calorimetry using LabMasterCell Metabolism 20, 670–677metabolic cages (TSE Systems) was used to
determine energy expenditure per gram of lean
body mass. Energy expenditure was calculatedas a function of O2 consumption and CO2 production according the following
formula: energy expenditure (kcal/hr) = ((3.941 3 vO2 (ml/hr)) + (1.1063 vCO2
(ml/hr)))/1,000. Body composition was measured using an EchoMRI-100 Body
Composition Analyzer. All experiments were approved by the Institutional
Animal Care and Research Advisory Committee of the University of Texas
Southwestern Medical Center or the University of Iowa.
Materials
Recombinant human FGF21 was from Novo Nordisk. Subcutaneous osmotic
pumpswere fromALZET. PD173074was fromSigma. a-helical CRF(9-41) was
from Phoenix Pharmaceuticals. The following kits were used to measure, October 7, 2014 ª2014 Elsevier Inc. 675
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FGF21 Activates the Sympathetic Nervous Systemmetabolic parameters: glucose (Wako Chemicals), triglycerides (Wako Chem-
icals), cholesterol (Fisher Scientific), insulin (Crystal Chem), leptin (Linco), and
adrenocorticotropic hormone. Liver triglyceride and cholesterol levels were
measured as described (Zhang et al., 2012).
Real-Time Quantitative PCR Analyses
Total RNA was extracted from liver using Stat 60 reagent (IsoTex Diagnostics).
For adipose tissue, RNeasy lipid tissue mini kits (QIAGEN) were used. RNA
(1–2 mg) from each sample was then used to generate cDNA (Invitrogen).
qPCR was performed using SYBR green as described (Bookout et al., 2006).
Sympathetic Nerve Activity Measurements
Measurement of sympathetic nerve activity to BAT was performed as
described (Harlan et al., 2011; Lockie et al., 2012; Morgan and Rahmouni,
2010). Following the establishment of baseline values, mice were pretreated
for 10 min with either vehicle (10 mM Na2HPO4, 2% [w/v] glycerol [pH 7.6]),
PD173074, or a-helical CRF(9-41) administered i.c.v. followed by i.c.v. or i.v.
(jugular vein infusion) administration of vehicle (10 mM Na2HPO4, 2% [w/v]
glycerol [pH 7.6]) or recombinant FGF21. SNA was recorded for an additional
4 hr. All i.c.v. injection volumes were 2 ml. The dose of PD173074 used (25 mg),
which had no effect on SNA on its own (Figure 4B), was based on a previous
publication in which PD173074 inhibited FGF19 action (Morton et al., 2013).
The dose of a-helical CRF(9-41) (6 mg) was based on a previous publication
in which this CRF antagonist blocked SNA activity in rats (Correia et al., 2001).
Statistical Analyses
Statistical analyses were performed by two-way ANOVAwith post hoc correc-
tion (GraphPad Prism) unless indicated otherwise. Data are presented as the
mean ± SEM; p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2014.07.012.
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